financetom
Business
financetom
/
Business
/
Shree Cement expects demand to grow 8-10% CAGR for next 4 years
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Shree Cement expects demand to grow 8-10% CAGR for next 4 years
Sep 26, 2022 7:40 AM

In this special show ‘Inside Out – On the Road’, the focus is on individual stocks with in-depth analysis, a deep dive into the financials, the key risks and triggers going forward. CNBC-TV18’s Nigel D'Souza visited Shree Cement’s Beawar unit in Jaipur to get a special deep dive into the same.

Shree Cement, in terms of a stock price in the last one month or so, has been an outperformer. Plus one year it has been a relative underperformer. But that doesn't take away from the fact that they have created big wealth for shareholders in the last one to two decades.

On the capacity addition front, they have moved from around 4 million tonnes towards 50 million tonnes. Now they are headed towards 80 million tonnes, which is the target that they have on their mind by 2030 or so.

Read Here:

Amidst industry consolidation, this Kanpur-based cement maker says it is not on the block

What's more important is they have been growing at a faster rate in comparison to the industry and they have been adding capacity at a lower than expected cost on a per tonne basis.

Speaking to CNBC-TV18, HM Bangur, MD of Shree Cement said the cement industry is in the sweet spot. He said the bottom line will definitely inflate. He expects cement demand to grow 8-10 percent compound annual growth rate, (CAGR) for the next 4 years.

In the ‘Swotlight’ segment, CNBC-TV18’s Sonal Bhutra talks about the paper sector and understands the value chain and everything about JK Paper.

Watch video for more.

Also Read: Century Textile optimistic about paper segment demand as supply disruptions ease

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Kura Oncology Gets FDA Approval for Komzifti in Acute Myeloid Leukemia
Kura Oncology Gets FDA Approval for Komzifti in Acute Myeloid Leukemia
Nov 13, 2025
11:44 AM EST, 11/13/2025 (MT Newswires) -- Kura Oncology ( KURA ) and Kyowa Kirin said Thursday the US Food and Drug Administration approved Komzifti for adults with relapsed or refractory acute myeloid leukemia carrying an NPM1 mutation. The approval is based on a study of 112 patients, in which about 21% achieved complete remission or complete remission with partial...
Blake Lively's lawsuit merely about reputation, should be thrown out, Baldoni says
Blake Lively's lawsuit merely about reputation, should be thrown out, Baldoni says
Nov 13, 2025
* Baldoni says Lively at fault for harm to reputation * Lively alleged hostile environment on film set * Lawyers for Lively not available for comment By Jonathan Stempel NEW YORK, Nov 13 (Reuters) - Justin Baldoni asked a U.S. judge to dismiss Blake Lively's lawsuit accusing the actor of sexually harassing and waging a smear campaign against her in...
TransDigm Beats Q4 Estimates, Sets 'Conservative' FY26 Guide Signaling Margin Reset, RBC Says
TransDigm Beats Q4 Estimates, Sets 'Conservative' FY26 Guide Signaling Margin Reset, RBC Says
Nov 13, 2025
11:49 AM EST, 11/13/2025 (MT Newswires) -- TransDigm Group ( TDG ) ended its fiscal year on a strong note, posting fiscal Q4 adjusted earnings per share of $10.82, above the roughly $10.00 consensus, on revenue of $2.44 billion, supported by strong defense demand and a rebound in commercial after market sales, RBC Capital said in a Wednesday note. For...
Pfizer Reports Completion Of Metsera Acquisition
Pfizer Reports Completion Of Metsera Acquisition
Nov 13, 2025
11:44 AM EST, 11/13/2025 (MT Newswires) -- Pfizer ( PFE ) said Thursday it has completed its acquisition of Metsera ( MTSR ) for about $7 billion in cash plus a contingent value right of up to $20.65 per share tied to the achievement of three specified clinical and regulatory milestones. The transaction is expected to be dilutive to Pfizer...
Copyright 2023-2026 - www.financetom.com All Rights Reserved